Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2011

Inhalt (33 Artikel)

Review

Endoscopic breast surgery: where are we now and what might the future hold for video-assisted breast surgery?

Daniel Richard Leff, Rajiv Vashisht, Gabriella Yongue, Mohammed Keshtgar, Guang-Zhong Yang, Ara Darzi

Review

Triple negative breast cancer: unmet medical needs

Sumanta Kumar Pal, Barrett H. Childs, Mark Pegram

Preclinical study

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Marcus Schmidt, Ilka Brigitte Petry, Daniel Böhm, Antje Lebrecht, Christian von Törne, Susanne Gebhard, Aslihan Gerhold-Ay, Cristina Cotarelo, Marco Battista, Wiebke Schormann, Evgenia Freis, Silvia Selinski, Katja Ickstadt, Jörg Rahnenführer, Martin Sebastian, Martin Schuler, Heinz Koelbl, Mathias Gehrmann, Jan G. Hengstler

Invited Commentary

Breast cancer prognostic markers in the post-genomic era

Lajos Pusztai, Takayuki Iwamoto

Preclinical study

Mutations and polymorphic BRCA variants transmission in breast cancer familial members

Brunella Pilato, Marianna Martinucci, Katia Danza, Rosamaria Pinto, Daniela Petriella, Rosanna Lacalamita, Michele Bruno, Rossana Lambo, Cosimo D’Amico, Angelo Paradiso, Stefania Tommasi

Preclinical study

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells

Stephen Hiscox, Peter Barnfather, Edd Hayes, Pamela Bramble, James Christensen, Robert I. Nicholson, Peter Barrett-Lee

Preclinical Study

COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients

Johanna G. H. van Nes, Esther M. de Kruijf, Dana Faratian, Cornelis J. H. van de Velde, Hein Putter, Claire Falconer, Vincent T. H. B. M. Smit, Charlene Kay, Marc J. van de Vijver, Peter J. K. Kuppen, John M. S. Bartlett

Preclinical Study

Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients

Esther M. de Kruijf, Johanna G. H. van Nes, Cornelis J. H. van de Velde, Hein Putter, Vincent T. H. B. M. Smit, Gerrit Jan Liefers, Peter J. K. Kuppen, Rob A. E. M. Tollenaar, Wilma E. Mesker

Preclinical study

Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene

Wei Jin, Yang Liu, Li Chen, Hua Zhu, Gen-hong Di, Hong Ling, Jiong Wu, Zhi-ming Shao

Preclinical study

Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes

Xiao-Hua Zeng, Zhou-Luo Ou, Ke-Da Yu, Lan-Yun Feng, Wen-Jing Yin, Jing Li, Zhen-Zhou Shen, Zhi-Ming Shao

Clinical trial

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern

Katharina E. Effenberger, Elin Borgen, Christine zu Eulenburg, Kai Bartkowiak, Andrea Grosser, Marit Synnestvedt, Rolf Kaaresen, Burkhard Brandt, Jahn M. Nesland, Klaus Pantel, Bjorn Naume

Invited Commentary

Disseminated tumor cells: the method is the message

John W. Park

Clinical trial

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability

J. Michael Dixon, Lorna Renshaw, Carolyn Langridge, Oliver E. Young, Mary McHugh, Linda Williams, Juliette Murray, E. Jane Macaskill, Fiona McCaig, Oliver M. Dixon, Lesley J. Fallowfield

Clinical trial

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

Dawn L. Hershman, Louis H. Weimer, Antai Wang, Grace Kranwinkel, Lois Brafman, Deborah Fuentes, Danielle Awad, Katherine D. Crew

Clinical trial

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Dino Amadori, Rosella Silvestrini, Mario De Lena, Francesco Boccardo, Andrea Rocca, Emanuela Scarpi, Francesco Schittulli, Mario Brandi, Roberta Maltoni, Patrizia Serra, Riccardo Ponzone, Nicoletta Biglia, Lorenzo Gianni, Amelia Tienghi, Maria Rosaria Valerio, Paola Bonginelli, Laura Amaducci, Marina Faedi, Editta Baldini, Angelo Paradiso

Clinical trial

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A. Woodward, James M. Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N. Hortobagyi, Fredika Robertson, W. Fraser Symmans, Lajos Pusztai, Naoto T. Ueno

Epidemiology

Outcomes following local therapy for early-stage breast cancer in non-trial populations

Nancy L. Keating, Mary Beth Landrum, John M. Brooks, Elizabeth A. Chrischilles, Eric P. Winer, Kara Wright, Rita Volya

Epidemiology

Supraclavicular recurrence after early breast cancer: a curable condition?

Anders N. Pedersen, Susanne Møller, Karina D. Steffensen, Vera Haahr, Merete Jensen, Mette M. Kempel, Søren L. Jepsen, Ebbe L. Madsen, Anne Roslind, Erik Sandberg, Claudia Schöllkopf, Peter G. Sørensen, Karen Margrethe Windfeldt, Michael Andersson

Epidemiology

RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies

Lin-Bo Gao, Xin-Min Pan, Li-Juan Li, Wei-Bo Liang, Yi Zhu, Lu-Shun Zhang, Yong-Gang Wei, Ming Tang, Lin Zhang

Epidemiology

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

Victor R. Grann, Priya R. Patel, Judith S. Jacobson, Ellen Warner, Daniel F. Heitjan, Maxine Ashby-Thompson, Dawn L. Hershman, Alfred I. Neugut

Epidemiology

Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis

Dae Sik Yang, Kyong Hwa Park, Ok Hee Woo, Sang Uk Woo, Ae-Ree Kim, Eun Sook Lee, Jae-Bok Lee, Yeul Hong Kim, Jun Suk Kim, Jae Hong Seo

Epidemiology

The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers

Irene Catucci, Paolo Verderio, Sara Pizzamiglio, Siranoush Manoukian, Bernard Peissel, Daniela Zaffaroni, Gaia Roversi, Carla B. Ripamonti, Barbara Pasini, Monica Barile, Alessandra Viel, Giuseppe Giannini, Laura Papi, Liliana Varesco, Aline Martayan, Mirko Riboni, Sara Volorio, Paolo Radice, Paolo Peterlongo

Epidemiology

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes

Madhura S. Mehta, Alexei Vazquez, Diptee A. Kulkarni, John E. Kerrigan, Gurinder Atwal, Shoichi Metsugi, Deborah L. Toppmeyer, Arnold J. Levine, Kim M. Hirshfield

Epidemiology

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

Daniel Prieto-Alhambra, M. Kassim Javaid, Sonia Servitja, Nigel K. Arden, Maria Martinez-García, Adolfo Diez-Perez, Joan Albanell, Ignasi Tusquets, Xavier Nogues

Brief Report

Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL® sample preparation

C. C. Ton, N. Vartanian, X. Chai, M. G. Lin, X. Yuan, K. E. Malone, C. I. Li, A. Dawson, C. Sather, J. Delrow, L. Hsu, P. L. Porter

Brief Report

Two novel variants in the 3′UTR of the BRCA1 gene in familial breast and/or ovarian cancer

Stéphanie Lheureux, Bernard Lambert, Sophie Krieger, Angelina Legros, Dominique Vaur, Christophe Denoyelle, Pascaline Berthet, Laurent Poulain, Agnès Hardouin

Brief Report

A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance

A. Gabriella Wernicke, Robert L. Goodman, Bruce C. Turner, Lydia T. Komarnicky, Walter J. Curran, Paul J. Christos, Imraan Khan, Katherine Vandris, Bhupesh Parashar, Dattatreyudu Nori, K. S. Clifford Chao

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.